Loading...

Renewed Distribution And Digital Adoption Will Improve Healthcare Supply Chains

Published
09 Feb 25
Updated
28 Aug 25
AnalystConsensusTarget's Fair Value
NZ$38.95
14.6% undervalued intrinsic discount
28 Aug
NZ$33.28
Loading
1Y
-7.6%
7D
-16.3%

Author's Valuation

NZ$38.9

14.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on28 Aug 25
Fair value Decreased 1.46%

A slight rise in EBOS Group’s future P/E ratio, with virtually unchanged revenue growth forecasts, suggests increased valuation multiples underpin a marginal decrease in the consensus analyst price target from NZ$39.53 to NZ$38.95. Valuation Changes Summary of Valuation Changes for EBOS Group The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from NZ$39.53 to NZ$38.95.

Shared on01 May 25
Fair value Decreased 3.41%

Shared on23 Apr 25
Fair value Increased 1.54%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 0.72%

AnalystConsensusTarget has increased revenue growth from 3.6% to 4.1%.

Shared on09 Apr 25
Fair value Increased 0.65%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 1.90%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.52%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 1.94%

AnalystConsensusTarget has decreased revenue growth from 4.1% to 3.3%.

Shared on12 Mar 25
Fair value Decreased 0.73%